<DOC>
	<DOCNO>NCT00014521</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness karenitecin treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Karenitecin Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose karenitecin patient recurrent malignant glioma receive receive anticonvulsant know metabolized P450 hepatic enzyme complex . - Determine pharmacokinetics drug patient . - Assess preliminary evidence therapeutic activity drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord use anticonvulsant know metabolized P450 hepatic enzyme complex ( yes v ) . Patients receive karenitecin IV 60 minute day 1-5 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos karenitecin accord continual reassessment method maximum tolerate dose ( MTD ) determine . The MTD define dose associate dose-limiting toxicity rate 33 % . Patients follow every 2 month . PROJECTED ACCRUAL : Approximately 3-24 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm anaplastic astrocytoma , anaplastic oligodendroglioma , glioblastoma multiforme Progressive recurrent disease previously treat radiotherapy without chemotherapy Prior lowgrade disease progress highgrade therapy allow Measurable disease MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm3 Hemoglobin least 8.5 g/dL Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Renal : Creatinine great 1.7 mg/dL Other : No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix breast No serious concurrent infection No medical illness would preclude study Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover No 1 prior chemotherapy regimen Endocrine therapy : Must stable dose steroid least 5 day Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy recover No 1 prior course radiotherapy Surgery : Not specify Other : No concurrent investigational agent At least 10 day since prior anticonvulsant drug induce hepatic metabolic enzyme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>